Charles River Laboratories (CRL) Q3 2024 earnings summary

Executive summary

• Third quarter 2024 financial performance exceeded expectations despite a challenging biopharmaceutical demand environment, with reported revenue down 1.6% year-over-year to $1.01 billion and organic revenue declining 2.7%.

• Revenue from small/mid-sized biotech clients was stable sequentially, while global biopharma revenue declined due to tighter budgets and restructuring.

• Decisive restructuring actions, including headcount reductions and site consolidations, are underway to align infrastructure with demand and generate significant cost savings.

• Record free cash flow was generated in Q3 2024, enabling stock repurchases and further debt reduction.

• Forward-looking demand indicators improved slightly, supporting the belief that the demand environment has stabilized.

Financial highlights

• GAAP operating margin was 11.6% (down 320 bps YOY); non-GAAP operating margin was 19.9% (down 60 bps YOY).

• GAAP EPS was $1.33 (down 21.3% YOY); non-GAAP EPS was $2.59 (down 4.8% YOY), both exceeding prior outlook.

• Free cash flow reached $213.1 million in Q3 2024, a record for the company.

• Cash and cash equivalents at quarter-end were $210.2 million, down from $276.8 million at year-end 2023.

Outlook and guidance

• 2024 revenue guidance narrowed to a decrease of 3.0% to 2.0% year-over-year; organic revenue expected to decline 4.0%–3.0%.

• Non-GAAP EPS guidance raised to $10.10–$10.30; GAAP EPS expected at $5.30–$5.50.

• Fourth quarter revenue expected to decline low to mid-single digits; non-GAAP EPS guidance for Q4 is $2.45–$2.65.

• Management expects restructuring actions to yield approximately $200 million in annualized cost savings by 2026, with $100 million impacting fiscal 2024.

• Current demand trends and biopharma restructuring are expected to persist into 2025.